Triple negative breast cancer, which accounts for 10–20% of all invasive breast cancer (BC) subtypes, is characterized by the lack of immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 and/or HER2 gene amplification. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.